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Summary
Background: O-fucose is added to cysteine-rich domains
called thrombospondin type 1 repeats (TSRs) by protein O-
fucosyltransferase 2 (POFUT2) and is elongated with glucose
by b3-glucosyltransferase (B3GLCT). Mutations in B3GLCT
result in Peters plus syndrome (PPS), an autosomal reces-
sive disorder characterized by eye and other developmental
defects. Although 49 putative targets are known, the function
of the disaccharide and its role in PPS remain unexplored.
Results: Here we show that while POFUT2 is required for
secretion of all targets tested, B3GLCT only affects the secre-
tion of a subset, consistent with the observation that B3GLCT
mutant phenotypes in PPS patients are less severe than em-
bryonic lethal phenotypes of Pofut2-null mice.O-glycosylation
occurs cotranslationally, as TSRs fold. Mass spectral analysis
reveals that TSRs from mature, secreted protein are stoichio-
metrically modified with the disaccharide, whereas TSRs
from protein still folding in the ER are partially modified, sug-
gesting thatO-glycosylation marks folded TSRs and promotes
ER exit. In vitro unfolding assays demonstrate that fucose and
glucose stabilize folded TSRs in an additivemanner. In vitro re-
folding assays under redox conditions showed that POFUT2
recognizes, glycosylates, and stabilizes the folded form of
TSRs, resulting in a net acceleration of folding.
Conclusions:While knownERquality-controlmachinery relyon
identifying and tagging unfolded proteins, we find that POFUT2
and B3GLCT mediate a noncanonical ER quality-control me-
chanism that recognizes folded TSRs and stabilizes them by
glycosylation. Our findings provide amolecular basis for the de-
fectsobserved inPPSandpotential targets that contribute to the
pathology.
Introduction
Thrombospondin type I repeats (TSRs) are small protein do-
mains characterized by the presence of six cysteines forming
three conserved disulfide bonds. Seventy-five percent of pre-
dicted TSRs contain the consensus sequence, CXX(S/T)
CXXG, for a rare modification called O-fucosylation catalyzed
by protein O-fucosyltransferase 2 (POFUT2) [1]. POFUT2 is
localized to the ER and in vitro only O-fucosylates properly
folded substrates [1–3]. In cell culture, O-fucosylation is
required for the secretion of two targets, ADAMTS13 and*Correspondence: robert.haltiwanger@stonybrook.eduADAMTSL1 [4, 5]. These observations led to hypothesis that
POFUT2 plays a role in folding and/or quality control of pro-
teins that contain TSRs [1, 2, 6].
TSRs with the POFUT2 consensus sequence are found in 49
proteins, including secreted matrix proteins such as thrombo-
spondin-1 (TSP1) and TSP2, and all members of the ADAMTS
and ADAMTSL families [7]. Several POFUT2 targets have
known physiological functions, and mutations in several are
associated with human pathologies [8]. Loss-of-function
mutations in mouse Pofut2 result in early embryonic lethality
that likely results from defects in one or more POFUT2 target
proteins [7].
The O-fucose on TSRs can be further extended with the
addition of glucose by b3-glucosyltransferase (B3GLCT) to
form a Glcb1-3Fuc disaccharide [6, 9]. The Glcb1-3Fuc disac-
charide has been confirmed on several putative targets,
including ADAMTS5, ADAMTS13, ADAMTSL1, TSP1, TSP2,
F-spondin, and Properdin [4, 5, 8, 10–12]. Mutations in human
B3GLCT cause a rare developmental disorder called Peters
plus syndrome (PPS), which is characterized by short stature,
anterior eye chamber defects, and cleft palate/upper lip,
among others [13–15]. Most disease-specific mutations in
B3GLCT result in alternative splicing of the mRNA, which
makes nonfunctional protein [15], although more recently
missense and truncation mutations have also been identified
[16]. Analysis of Properdin from serum of PPS patients shows
a total loss of Glc from the TSRs, suggesting these patients are
essentially null for B3GLCT [14].
Though the involvement of B3GLCT in PPS has been known
for many years, the molecular details for how these rare post-
translational modifications affect protein function are poorly
understood. In this work, we use cell-based and in vitro assays
to gain insight into why addition of the Glcb1-3Fuc disaccha-
ride to TSRs is important for their function. Our results confirm
that while POFUT2 is required for secretion of all targets
tested, B3GLCT affects secretion of targets to varying extents.
We propose that POFUT2 and B3GLCT mediate a novel qual-
ity-control mechanism for recognizing,modifying, and stabiliz-
ing a folded structure. Since PPS is less severe than the
Pofut2-null phenotype, we hypothesize that defects in only a
subset of POFUT2 targets contribute to the PPS pathology.
Results
POFUT2 and B3GLCT Are Required for the Secretion of
Their Substrates to Different Extents
Embryonic lethality of Pofut2 mice is seen around embryonic
day 7.5 (E7.5), and all but ten POFUT2/B3GLCT targets are ex-
pressed at this stage [7]. Prior work has demonstrated that
small interfering RNA (siRNA) knockdown of POFUT2 results
in loss of ADAMTS13 secretion. Since ADAMTS13 is not ex-
pressed at E7.5, other targets must contribute to the Pofut2-
null phenotype. To examine whether the secretion defect
seen in ADAMTS13 extends to other targets, we looked at
the effects of POFUT2 siRNA knockdown in HEK293T cells ex-
pressing TSR1-3 from TSP1 [called TSP1(TSR1-3) henceforth],
ADAMTSL1 and ADAMTSL2 (Figure 1A). Reduction of POFUT2
severely impacted the secretion of all of these proteins
Figure 1. B3GLCT Is Required for Secretion of Some, but Not All, POFUT2 Targets
(A) Domain map of POFUT2 targets tested.
(B) siRNA specific for POFUT2, B3GLCT, or nonspecific control were cotransfected into HEK293T cells with plasmids encoding tagged POFUT2 targets
[ADAMTS13, ADAMTSL1, ADAMTSL2, and TSP1(TSR1-3)] or human immunoglobulin G (IgG) heavy chain. Media and cell lysates were evaluated bywestern
blot (red, anti-V5 or anti-myc; green, anti-IgG).
(C) Quantitation of data from (B). Data are the mean 6 SD (n = 3).
287(Figures 1B and 1C). In contrast, knockdown of B3GLCT had a
more selective effect, with very little impact on ADAMTS13
secretion but significant reduction in secretion of ADAMTSL1,
ADAMTSL2, and TSP1(TSR1-3) (Figure 1). Taken together,
these results suggest that POFUT2 is required for secretion
of proteins with TSRs containing the consensus sequence,
while B3GLCT is essential for trafficking a subset of POFUT2
targets.
O-Fucosylation of TSR-Containing Proteins Occurs
Cotranslationally in the ER
Although POFUT2 localizes to the ER, the source of the donor
substrate, GDP-fucose, in the ER is unclear, at least in mam-
mals. Hence it remains unknown where O-fucosylation occurs.
If O-fucosylation by POFUT2 is part of a quality-control
pathway, addition of fucose to TSRs would be an ER-associ-
ated event. Both POFUT2 and B3GLCT are soluble proteins
that localize to the ER [1, 6, 9]. If GDP-fucose is present in the
ER,POFUT2couldO-fucosylate TSRscotranslationally, playing
an active role in the folding of TSRs. Alternatively, POFUT2
could bind substrates in the ER and shuttle to the ER-Golgi
intermediate compartment (ERGIC), where there is a putative
GDP-fucose transporter [17], or to the Golgi, where there is a
well-describedGDP-fucose transporter [18]. Once fucosylated,
substrates could move on in the secretory pathway while
POFUT2 cycles back to the ER [3].
To differentiate these possibilities, we determined the sub-
cellular location of O-fucosylation using a bioorthogonal
analog of fucose, 6-alkynylfucose (6AF). The alkyne group
can be covalently modified with azido-biotin using ‘‘click’’chemistry for easy detection [19]. We used ADAMTS13
and ADAMTSL1 as model substrates. ADAMTS13 has ten
N-glycosylation sites and seven O-fucosylation sites [4],
while ADAMTSL1 has one N-glycosylation site in addition
to its four O-fucosylation sites [5]. Using endoglycosidase
H (EndoH) sensitivity as a measure of N-glycan process-
ing, we can determine whether cell-associated ADAMTS13
or ADAMTSL1 is in the ER or has progressed further
through the secretory pathway. 6AF-labeled ADAMTS13 or
ADAMTSL1 purified from HEK293T cells was subjected to
digestion with either EndoH or peptide N-glycanase F (PNGa-
seF). Western blot analysis of the digested samples (Fig-
ure 2A) showed that the bulk of cell-associated ADAMTS13
and ADAMTSL1 was sensitive to EndoH, confirming the ER
localization of these proteins. PNGaseF served as a positive
control since it cleaves all types of N-glycans. Analysis of
ADAMTSL1 from media showed EndoH-resistant, PNGaseF-
sensitive, O-fucosylated protein, consistent with the acquisi-
tion of complex-type modification in the Golgi (Figure 2A,
shown for ADAMTSL1; ADAMTS13 levels are low in the me-
dium, making this analysis difficult). Although these data sug-
gest that O-fucosylation of TSRs occurs in the ER, they do
not rule out the possibility that the protein is O-fucosylated
in the ERGIC.
To determine whether O-fucosylation of TSRs occurs
before the protein moves to the ERGIC, we examined whether
O-fucosylation is a cotranslational process by analyzing the
fucosylation status of ribosome-associated ADAMTS13.
HEK293T cells cultured in the presence of 6AF were trans-
fected with N-terminal 3XFlag-ADAMTS13 and treated briefly
Figure 2. O-Fucosylation Occurs in the ER and Is
at Least Partly Cotranslational
(A) 6AF-labeled ADAMTS13-V5-His6 or
ADAMTSL1-myc-His6 was immunoprecipitated
from cell lysates or Ni-NTA enriched from media
(sufficient ADAMTS13 could not be obtained
frommedia fractions). Purified proteins were sub-
jected to EndoH or PNGaseF digest and analyzed
by western blots with the indicated antibodies
(red anti-V5 or anti-myc; green, streptavidin).
(B) Ribosomes were isolated from HEK293T cells
transfected with either empty vector or plasmid
encoding 3XFlag-ADAMTS13 and labeled with
6AF. Nascent polypeptides were detected with
anti-Flag (red), and 6AF was detected with strep-
tavidin (green). Asterisks indicate background
bands that appear in the empty vector controls.
See also Figure S1.
288with cycloheximide (CHX) to block polypeptide elongation.
Ribosomes were purified using sucrose cushion ultracentrifu-
gation, and western blot analysis of the ribosome fraction
showed distinct bands of nascent polypeptides labeled with
6AF in ADAMTS13 transfected samples, indicating the pres-
ence of O-fucose (Figure 2B). The bands labeled with 6AF
were above 50 kDa, which corresponds to the size of a
polypeptide translated past the first TSR on ADAMTS13.
Similar results were seen when HEK293T cells expressing
ADAMTS13 were treated with puromycin, a translational in-
hibitor that covalently attaches to the growing polypeptide
chain (Figure S1) [20]. Western blot analysis of ADAMTS13
immunopurified from HEK293T cells treated with puromycin
showed that truncated polypeptides labeled with 6AF also
react with the anti-puromycin antibody (see overlay). These
results strongly argue that O-fucosylation is cotranslational
and occurs in the ER and that O-fucosylation occurs while
TSRs are folding.
Glycosylation Marks Folded TSRs and Is Required for
ER Exit
The results in Figure 2 suggest that majority of the cell-
associated TSR-containing proteins are in the ER and that
O-fucosylation occurs early in protein synthesis. To deter-
mine the efficiency of O-fucosylation on individual TSRs of
ADAMTS13, we performed semiquantitative mass spectralanalysis on protein purified from condi-
tioned media and cell lysates. Consis-
tent with previously published results
[4], we found that peptides from
TSR5, TSR7, and TSR8 of mature
ADAMTS13 purified from the medium
were efficiently modified, with the ma-
jor glycoform being the disaccharide,
Glcb1-3Fuc (Figures 3A and S2A and
Table S1). In contrast, a mixture of un-
modified and glycosylated peptides
were detected on ADAMTS13 isolated
from cell lysates, with the majority be-
ing unmodified (Figure 3A). Interest-
ingly, the C-terminal site (TSR8) was
more poorly modified than N-terminal
sites (TSR5 and TSR7), suggesting
that glycosylation of TSR8 occurs after
glycosylation of the other TSRs. Theseresults confirm that the cell-associated protein is only
partially modified.
Since POFUT2 onlymodifies properly folded TSRs in vitro [2],
we predicted that the unmodified peptides in cells would be
from incompletely folded TSRs, whereas the glycosylated pep-
tides would be from folded TSRs. To separate populations of
ADAMTS13 with unfolded TSRs containing unpaired cysteines
from properly folded TSRs, we lysed cells in the presence of
excess iodoacetamide. Immunopurified ADAMTS13 was then
analyzed by reducing and nonreducing SDS-PAGE (Figure 3B).
The mature protein from the medium migrated at its expected
size under both reducing and nonreducing conditions, showing
that it no longer has unpaired cysteines. Under reducing condi-
tions, cell-associated protein migrated at the predicted size
regardless iodoacetamide treatment. In the absence of iodoa-
cetamide, all of the cell-associated protein ran as an aggregate
at the top of the nonreducing gel, suggesting that all cell-asso-
ciated ADAMTS13 has at least one unpaired cysteine. When
cellswere lysed in the presence of iodoacetamide,weobserved
that some of the protein migrates at the size of the mature pro-
tein on the nonreducing gel. This population most likely has
fewer unpaired cysteines (i.e., is more completely folded) than
the aggregate at the top of the gel. Mass spectral analysis of
these populations revealed that the majority of the peptides
derived from the aggregate are not glycosylated (Figure 3C),
consistent with the TSRs being mostly unfolded in this protein
Figure 3. Properly Folded TSRs Are Marked with O-Fucose Disaccharide in Cells
(A) ADAMTS13 was purified from media or cell lysate fractions of HEK293T cells transfected with plasmid encoding ADAMTS13. Purified ADAMTS13 was
subjected to reduction/alkylation, trypsin digestion, and analysis by nano-liquid chromatography-tandem mass spectrometry as described in the Experi-
mental Procedures. Extracted ion chromatograms (EICs) of the ions corresponding to unmodified (black) andO-fucose mono- (red) and disaccharide (blue)
glycoforms of the peptides containing the O-fucosylation site from TSR5, TSR7, and TSR8 derived from ADAMTS13 are shown. Details of the ions repre-
senting each glycoform used to prepare the EICs are listed in Table S1 and Figure S2A.
(B) HEK293T cells transfected with 3XFlag-ADAMTS13 were lysed in the presence of 100 mM iodoacetamide (IoA). Aliquots from the cell lysates were
analyzed by western blot under nonreducing (top) and reducing (bottom) conditions. Treatment of the samples with reducing agents (bottom) led to com-
plete reduction of ADAMTS13, making the two populations indistinguishable. Mature form of ADAMTS13 isolated frommedium is provided as a control for
fully folded protein (migration position marked with an asterisk).
(C) EICs (prepared as in A) of peptides from unfolded aggregates (top of gel from B) and mostly folded (migrating with mature protein at the asterisk from B)
cell-associated ADAMTS13 showing predominantly unmodified peptides from TSR5, TSR7, and TSR8 in the aggregate, but majority glycosylated peptide
from TSR5 and TSR7 in the mostly folded fraction.
(D) Lec13 CHO cells were transfected with plasmids encoding the tagged POFUT2 targets shown or IgG as a negative control. Each target was immuno-
precipitated from cell lysates and western blotted with anti-tag antibodies or with anti-BiP. The cells were rescued by addition of 1mM fucose exogenously.
Quantitation represents relative amounts of BiP/protein without fucose normalized to 1. Note that BiP was not detected in the IgG immunoprecipitate. Data
are the mean 6 SD from three independent experiments.
See also Figure S2 and Table S1.
289population. In contrast, peptides from the band corresponding
to the band comigrating with mature protein showed almost
fully glycosylated TSR5and TSR7, while TSR8was still predom-
inantly unmodified. This suggests that the TSRs in this protein
population are mostly folded and will exit the cell upon the
folding and glycosylation of TSR8. These data demonstrate
that glycosylation serves as amarker for the folded TSRswithin
the cell and that glycosylationmust be complete prior toERexit.The presence of a ‘‘mark’’ implies theremay be receptor that
recognizes the mark that would promote ER exit, or that the
lack of themark is recognized by somemechanism that retains
the unmarked TSRs in the ER. We hypothesized that there
could be either a lectin-like protein that recognizes O-fucose
glycans and promotes their ER exit or there could be a chap-
erone/oxidoreductase that actively binds to unfolded TSRs
and keeps them in the ER. To address these possibilities, we
290used GDP-mannose 4,6 dehydratase (GMD) mutant Lec13
CHO cells that cannot synthesize GDP-fucose de novo [21].
The mutant can be rescued by addition of L-fucose exoge-
nously to the cell culture medium, which is taken up by the
salvage pathway and converted to GDP-fucose. In this sys-
tem, we used ADAMTS13 as bait to look for interacting pro-
teins in the presence of a thiol-cleavable crosslinker, dithiobis
[succinimidyl propionate] (DSP). We observed enrichment of
an w80 KDa protein in the absence of fucose (Figure S2B),
which we identified as binding immunoglobulin protein (BiP)
using mass spectrometry. We confirmed this observation by
coimmunoprecipitation of several proteins (without DSP) and
western blotting. Expression of TSR-containing proteins did
not affect BiP levels compared to the immunoglobulin G
(IgG) control regardless of the presence of fucose, suggesting
that the unfolded protein response (UPR) is not being induced
in this situation (Figure S2C). All proteins tested coprecipitated
more BiP in the absence of fucose than in its presence
(Figure 3D). These results suggest that ER retention of these
proteins in the absence of O-fucosylation is mediated by
enhanced interactions with ER chaperones such as BiP.
Addition of the Glcb1-3Fuc Disaccharide Stabilizes Folded
TSRs
The data above show thatO-fucosylation occurs during folding
in the ER and validates that only properly folded TSRs are fuco-
sylated in vivo. To determine how the addition of fucose and
glucose could affect the folding of the TSR-containing proteins
in cells, we evaluated the effect of the sugars on the stability of a
folded TSR in vitro. Previous structural studies demonstrated
that O-fucosylation does not considerably alter the structure
of a TSR [6]. However, the possibility that O-fucosylation may
lend thermodynamic stability to the TSR has not been explored.
To test this, wemodified bacterially expressed TSR3 fromTSP1
(TSP1-TSR3) [2] with either fucose (Fuc-TSR) or the Glcb1-3Fuc
disaccharide (GlcFuc-TSR) in vitro using purified enzymes. The
TSRswere thenunfoldedusing lowconcentrationsof guanidine
hydrochloride and dithiothreitol (DTT). Differences in hydropho-
bicities of unfolded and folded isoforms allow analysis of the
unfolding reaction by reverse-phase high-performance liquid
chromatography (HPLC). Sampling at various time points
showed that the Fuc-TSR is more resistant to denaturation
than theunmodifiedTSR (Figure4A). Theadditionof theglucose
further increases the resistance to chemical denaturation.
Quantitation of the data in Figure 4A shows that the halfway
point of the unfolding reaction, indicated by the intersection of
the plots of unfolded and folded populations, increases with
the addition of each sugar (Figure 4B). Since unfolding rate is
a reflection of the equilibrium between the unfolded and folded
states (Figure 4B, schematic), these results strongly argue that
addition fucose andglucose stabilize foldedTSRs in an additive
manner and accelerate the net folding rate of TSRs.
POFUT2 Accelerates the Folding of TSRs In Vitro
If O-fucosylation stabilizes folded TSRs, and POFUT2 only
modifies properly folded TSRs [1], O-fucosylation should shift
the folding equilibrium toward the folded state, accelerating
the net folding rate. We tested this using an in vitro refolding
assay with bacterially expressed TSP1-TSR3, recombinant
POFUT2 and GDP-fucose. TSP1-TSR3 was completely dena-
tured and was then allowed to refold in the presence of redox
agents. The reaction was sampled at various time points and
folding intermediates were acid trapped. These conditions
allow creation of a folding equilibrium between the unfolded,intermediate, and folded forms of the TSR (U, I, and F, respec-
tively, in Figure 5A). Addition of POFUT2 to the redox system
did not have a significant effect on the rate of folding, but
when the reaction was supplemented with both POFUT2 and
GDP-fucose, the rate of formation of folded TSR significantly
increased (Figure 5A). Quantitation of the unfolded TSR (U)
and the folded TSR (F) across the different conditions and
time points showed that although the amount of unfolded
protein decreased at roughly the same rate, the rate of appear-
ance of the folded TSR was much higher in the presence of
POFUT2 and GDP-fucose (Figure 5C). When the reaction
mixture was analyzed by mass spectrometry, the majority of
the TSP1-TSR3 population was O-fucosylated 90 min into
the reaction in the presence of POFUT2 and GDP-fucose
(Figure S3A and Table S2). These results demonstrate that
POFUT2 accelerates the net rate of TSR folding in the pres-
ence of GDP-fucose.
Though GDP-fucose alone does not have an effect on TSR
refolding (Figure S3B), it appears to be a requirement in PO-
FUT2-mediated refolding of TSP1-TSR3. It was necessary to
distinguish between two possibilities: (1) that binding GDP-
fucose was a structural necessity for substrate binding and/
or recognition or (2) that fucosyltransferase activity is required
for the folding of TSP1-TSR3. The POFUT2-E54A mutant has
previously been shown to have no fucosyltransferase activity
[23] (Figure S3C). In vitro folding assays performed using
wild-type (WT) and E54A mutant enzyme in the presence of
GDP-fucose showed that fucosyltransferase activity is neces-
sary for altering the rate of folding (Figures 5B and 5C). The
E54Amutant did not affect the rate of folding of the TSR. These
data suggest that both the catalytic activity and GDP-fucose
are required for POFUT2 to affect folding. In addition, a homo-
log of POFUT2 with distinct specificity, POFUT1, had no effect
on TSR folding (Figures S3D and 5C) demonstrating the spec-
ificity of this reaction. Finally, addition of GDP (not GDP-
fucose) and WT POFUT2 also had no effect on folding
(Figure S3E). Thus, fucosylation of the TSR by POFUT2 accel-
erates the rate of TSR folding, suggesting that in the absence
of O-fucosylation, POFUT2 target proteins fold inefficiently,
leading to an accumulation of misfolded protein and reduced
secretion.
Discussion
Nearly 30% of all known proteins have disulfide bonds [24].
The appropriate pairing of the cysteines in a crowded environ-
ment like the ER poses a challenge to the folding and quality-
control machinery. In this complex mixture, it makes strategic
sense for the cell to have dedicated quality-control mecha-
nisms for different types of cysteine-rich motifs in addition to
the generic network of oxidoreductases and chaperones.
POFUT2 and B3GLCT fall into this category. Each TSR has
six cysteines, and most POFUT2 targets have multiple tandem
TSRs. A protein such as ADAMTS13 has eight TSRs with 46
cysteines (just in the TSRs) that must pair correctly. Our data
suggest that the more TSRs found in a protein, the greater
the need for a specialized quality-control system such as
described here (Figure S4). We propose that POFUT2 and
B3GLCT assist in the quality control of TSR folding to help
resolve this complexity.
The main function of the POFUT2-B3GLCT machinery is to
recognize and modify properly folded TSRs, stabilizing the
folded structure, possibly in a processive manner (from N- to
C-terminal) (Figure 6A). The most-N-terminal TSR will interact
Figure 4. Fucose and Glucose Stabilize Folded TSRs in an Additive Manner
(A) Equivalent amounts of unmodified, Fuc-TSR, and GlcFuc-TSR (all TSP1-TSR3) were incubated with denaturants in an in vitro melting reaction. Aliquots
were removed at the indicated times and analyzed by reverse-phase HPLC. TSR levels were monitored by absorbance at 214 nm (U, unfolded isoform; F,
folded isoform). Note that Fuc-TSR and GlcFuc-TSR were not completely unfolded within the 80 min time course, so they were completely denatured by
incubation for 80 min in 30 mM DTT.
(B) U and Fwere quantified by determining the area under the curve (AUC) for each population of TSR in themelting reaction in (A). Valueswere normalized to
U at t = 80 min for TSR and completely denatured Fuc-TSR and GlcFuc-TSR (30 mM DTT) were set to 100%. Schematic on the right shows the unfolding
reactions as equilibria, with weighted arrows representing the favored reaction (orange line, disulfide bond; red triangle, fucose; blue circle, glucose). Data
are the mean 6 SD from three or more independent experiments.
291with chaperones (such as BiP) and oxidoreductases (labeled
PFC [protein folding complex] in Figure 6) that assist in folding
when it arrives in the ER, allowing it to enter a folding equilib-
rium much like those observed during the in vitro folding of
TSP1-TSR3 in Figure 5A (indicated by the double-headed ar-
row in Figure 6A, i). POFUT2 (previously loaded with GDP-
fucose) binds a correctly folded TSR isomer (Figure 6A, ii).
O-fucosylation of the TSR stabilizes the folded structure,
driving the folding equilibrium forward (indicated by the thick
arrow in Figure 6A, iii), accelerating the folding of the TSR.
B3GLCT then adds glucose, further stabilizing the folded
TSR, shifting the equilibrium more (indicated by the second
thick arrow in Figure 6A, iv). The cycle is then repeated forthe next TSR (Figure 6A, v), and so on until a chain of fully
folded and glycosylated TSRs emerges (Figure 6A, vi). Fully
O-glycosylated protein can then exit the ER because the
PFC no longer associates with the folded TSRs. Once a TSR
folds, hydrophobic patches will be buried and cysteines in
disulfide bonds, and thus the TSR will no longer interact with
the chaperones and oxidoreductases of the PFC. In the
absence of POFUT2, TSR foldingwill stall in the folding equilib-
rium, causing continued interactions with the PFC. Ultimately,
the misfolded protein would be degraded in the cell. Although
O-fucosylation on its own may be sufficient to stabilize some
TSRs (e.g., those from ADAMTS13; Figure 1), other TSRs
require addition of glucose by B3GLCT for efficient folding
Figure 5. O-Fucosylation by POFUT2 Accelerates the Net Folding Rate of TSRs
(A) Bacterially expressed (unmodified) TSP1-TSR3 was denatured and refolded in vitro in the presence of redox agents (black), redox and POFUT2 (blue), or
redox, POFUT2, and GDP-fucose (red). Aliquots were removed at the indicated times and analyzed using reverse-phase HPLC (U, unfolded TSR; F, folded
TSR; I, folding intermediates).
(B) In vitro refolding assay (as in A) in the presence of GDP-fucose using POFUT1 (black), a closely relatedO-fucosyltransferase thatmodifies properly folded
epidermal growth factor-like repeats [22], as a negative control, WT POFUT2 (red), and the catalytically inactive POFUT2-E54A (blue).
(C) Quantitation of unfolded and folded products by AUC in (B) shows the rate of disappearance of unfolded protein (top) and rate of formation of folded
protein (bottom).
See also Figure S3 and Table S2.
292and secretion [e.g., from ADAMTSL1, ADAMTSL2, and
TSP1(TSR1-3); Figure 1].
Recent structural studies indicate that in addition to the TSR
binding site, POFUT2 has a hydrophobic patch that could
interact with an adjacent TSR [23]. This would allow POFUT2
to physically separate adjacent TSRs and enable their interac-
tions with the PFC (Figure 6A, ii).
Our results provide first insights into the role of B3GLCT in
PPS. Although ADAMTS13 secretion was only minimallyaffected when B3GLCT was knocked down, secretion of
several other proteins [ADAMTSL1, ADAMTSL2, and TSP1
(TSR1-3)] was profoundly reduced (Figure 1). Hess and co-
workers demonstrated that serum levels of Properdin were
reduced about 50% in PPS patients relative to controls
[14]. These results suggest that addition of glucose affects
secretion of proteins to different extents. The results also
correlate nicely with the PPS phenotype. For instance,
PPS patients do not show symptoms of ADAMTS13
Figure 6. A Model for POFUT2 in the Folding of
TSRs
See the Discussion.
293deficiency, which results in a blood clotting disorder called
Thrombotic thrombocytopenic purpura [25]. Similarly, PPS
patients have no reported defects in activation of the
alternative complement pathway, suggesting that serum
levels of Properdin are sufficient [13]. However, patients
with Geleophysic dysplasia (GD), caused by mutations in
ADAMTSL2 that result in reduced secretion [26], show
several common symptoms with PPS patients, such as short
stature, unusual facial features and brachydactyly [13, 26].
Taken together, these independent observations suggest
that PPS is a collective disorder of individual pathologies
caused by secretion defects in a subset of B3GLCT target
proteins.
The identification of O-fucosylated nascent proteins
(Figure 2B) strongly argues in favor of GDP-fucose presence
in the ER. Though an ER GDP-fucose transporter has been
identified in Drosophila [18], the mammalian homolog of
this protein has been demonstrated to have UDP-xylose,
not GDP-fucose, transporter activity [27]. Possible models
to explain GDP-fucose availability in the ER are retrograde
transport of GDP-fucose from the ERGIC or Golgi, where
there are known GDP-fucose transporters (Slc35C1 and C2
[17, 28]) or cycling of POFUT2 itself to these compartments
where it could bind GDP-fucose. Of course, there still remains
the possibility of an as yet unidentified ER-associated GDP-
fucose transporter.
The fact that POFUT2 recognizes and modifies a folded
structure distinguishes it from other ER quality-control sys-
tems. The UDP-glucose:glycoprotein glucosyltransferase
recognizes hydrophobic patches on unfolded proteins,
modifying them with glucose so that they can participate
in another round of folding with calnexin or calreticulin
[29, 30]. In contrast, we propose that POFUT2 is able to
selectively modify a properly folded TSR. O-fucosylation
of the TSR stabilizes the folded motif, preventing it from
forming incorrect disulfide bonds with the adjacent newly
synthesized TSR. The net result drives the folding equilib-
rium forward. Addition of glucose by B3GLCT further stabi-
lizes the folded TSR, which appears to be required for
proper folding of some proteins but not others. The crystal
structure of TSR3 from TSP1 shows the O-fucosylated
amino acid to be located in a loop preceding the first of
two b sheets [31]. Previous studies have suggested that
the core N-linked N-acetylglucosamine stabilizes local
loop structures in proteins and that stability is enhanced
by addition of the mannoses [32]. The addition of fucose
and glucose may have a similar effect on the loop they
modify in TSRs.Experimental Procedures
Plasmids Used in This Study
The preparation of full-length pcDNA4.0
ADAMTS13-V5-His6 construct was described
previously [4]. Truncation mutants were gener-
ated from this plasmid and ligated into pcDNA4.0
V5-His6 (Invitrogen). The N-terminal 3XFlag-
tagged ADAMTS13 construct was generated by
ligation of a 3XFlag fragment containing HindIII/
BamHI sites (amplified from p3XFlag-CMV;Sigma) into pSecTag2 HygroC to generate an N-terminal 3XFlag-containing
vector. Full-length ADAMTS13 with XhoI overhangs was then ligated into
this vector to generate the N-3XFlag-ADAMTS13 construct. Plasmids en-
coding human IgG, TSP1(TSR1-3)-myc-His6, ADAMTSL1-myc-His6, and
ADAMTSL2-myc-His6 constructs were as described previously [5, 19, 33,
34]. Human POFUT2 constructs (WT and E54A) were a generous gift from
Heinz Gut [23]. B3GLCT construct was obtained from RIKEN (Clone ID
G830038O03) and was subcloned into pSecTag2 HygroC.
siRNA Experiments
siRNA targeting POFUT2 was the same as used previously [4], and Stealth
siRNAs (Life Technologies) targeting B3GLCT were obtained (sense, 50-
CCUCCUUCAUCAGCUGGCUAAACAA; antisense, 50-UUGUUUAGCCAG-
CUGAUGAAGGAGG). siRNA and plasmid DNA encoding proteins of interest
were cotransfected using Lipofectamine 2000 (Life Technologies) in
HEK293T cells according to the manufacturer’s protocol. The cells were
then allowed to grow in OptiMEM for 48 hr before harvesting of media and
cell fractions. Equal fractions of media and cell lysate were analyzed by
western blotting. Imaging and quantitation was performed using an Odys-
sey 9120 infrared imaging system (Li-Cor).
Azide-Alkyne Cycloaddition/Click Reaction
Reactions were performed as described previously [19]. Media and cell
lysate fractions were collected from cells metabolically labeled with
200 mM 6AF and tagged with Biotin [0.1 mM Azido-Biotin (CC Tools),
0.1 mM Tris-(benzyltriazolylmethyl)amine catalyst (AnaSpec), 1 mM copper
sulfate, and 2 mM sodium ascorbate] at room temperature for 1 hr.
EndoH and PNGaseF Digests
HEK293T cells were transiently transfected with ADAMTS13-V5-His6 or
ADAMTSL1-myc-His6 and labeled with 200 mM6AF for 48 hr. Media samples
were purified using Ni-NTA agarose (QIAGEN), and lysates were immuno-
purified using anti-V5 (Invitrogen) or anti-myc (9E10). Samples were
‘‘clicked’’ as described above and treated with PNGaseF or EndoH as
described [35].
Ribosome Experiments
HEK293T cells transiently transfected with N-3XFlag-ADAMTS13 plasmid
and labeled with 200 mM 6AF for 24 hr and were then treated with 100 mM
cycloheximide (Sigma) for 15 min at 37C. The cells were then lysed in
50 mM NH4HCl, 12 mMMgCl2, 50 mM Tris acetate, and 0.5% NP-40. The ly-
sates were passed through a 27.5 gauge syringe twice to thoroughly free
any adherent ribosomes, and debris was removed by centrifuging at
12,000 g (20 min at 4C). The lysate was ‘‘clicked’’ (as described above)
and loaded on a 34% sucrose cushion containing 50 mM NH4HCl, 12 mM
MgCl2, and 50 mM Tris acetate and was centrifuged at 100,000 g for 3 hr.
The pellet was rinsed three times with lysis buffer, resuspended in sample
buffer, and analyzed by western blotting (anti-Flag [Sigma], Streptavidin IR-
Dye 800 [Rockland Immunochemicals]), and imaging was performed with
the Odyssey system.
Analysis of Cell-Associated ADAMTS13
HEK293T cells were transiently transfected with N-3XFlag-ADAMTS13
plasmid and allowed to grow for 48 hr before being lysed in RIPA buffer con-
taining 100 mM iodoacetamide (Sigma). The lysates were incubated on ice
for 30 min to allow alkylation before insolubles were cleared by
294centrifugation at 20,000 g for 10 min. After immunoprecipitation (Flag-M2
agarose beads, Sigma) and elution (3XFlag peptide, Sigma), the eluate
was divided and run on reducing and nonreducing gels and was detected
by western blot analysis. Relevant bands were subjected to in-gel protease
digestions and mass spectral analysis as described [8]. Semiquantitative
analysis of different glycoforms of each peptide was performed by genera-
tion of extracted ion chromatograms as described [36].
Coimmunoprecipitation Experiments
Lec13 CHO cells were grown in the presence or absence of 1 mM fucose and
transiently transfected with plasmids encoding the indicated TSR-containing
protein.At 24hrafter transfection, thecellswere lysedand theTSR-containing
protein was immunoprecipitated with antibodies against the respective tags.
The eluates were analyzed on a reducing gel and probed with the indicated
antibodies.
In Vitro Unfolding Assay
TSP1-TSR3was generated in BL21 cells as described [2]. Fuc-TSRwas syn-
thesized by incubation of TSP1-TSR3 (10 mM) with 200 mMGDP-fucose and
POFUT2 in buffer containing 50 mM HEPES (pH 6.8) overnight at 37C. The
fucosylated TSR was repurified from the reaction mixture using reverse-
phase HPLC and was used in a similar reaction with recombinant B3GLCT
and UDP-glucose to generate GlcFuc-TSR. TSRs were incubated with
0.6 M guanidine hydrochloride and 2 mM DTT at room temperature. At the
specified time points, aliquots of the unfolding reaction were acid trapped
and analyzed by reverse-phase HPLC as described in [37]. Folded and
unfolded species were quantified by determining the AUC for each species.
For quantitation, the AUC for each peak was measured using curve symme-
try, and the background AUC was subtracted and calculated as a percent-
age of the starting material (total TSR at 0 min).
In Vitro Folding Assay
TSP1-TSR3 was denatured in 100 mM Tris (pH 7.5), 6 M GnHCl, and 10 mM
DTT at room temperature for 1.5 hr. Denaturants were removed using a Se-
phadex G-25 column (Pharmacia). The desalted protein was then allowed to
refold in the presence of 25 mM GSSG, 50 mM GSH (Sigma), and combina-
tions of equimolar recombinant POFUT2 and 200 mM GDP-fucose (final). At
the specified time points, aliquots of the reaction were taken and acid trap-
ped in 4% trifluoroacetic acid (final). The samples were then analyzed by
reverse-phase HPLC as described in [37]. POFUT2 (WT and E54A) was ex-
pressed and purified from HEK293T cells as described in [23]. Quantitation
was determined using AUC as described above.
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